






EPIZYME PIPELINE

PROGRAM	TREATMENT APPROACH	POPULATION	RESEARCH	PHASE 1	PHASE 2	PHASE 3	APPROVED	
TAZVERIK® (tazemetostat)^a								
Epithelioid Sarcoma^a	Monotherapy	Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.	Approved by US FDA in Jan 2020					
Non-Hodgkin Lymphoma^a	Monotherapy	<ul style="list-style-type: none"> Adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies. Adult patients with relapsed or refractory FL who have no satisfactory alternative treatment options. 	Approved by US FDA in Jun 2020					
TAZEMETOSTAT								
Non-Hodgkin Lymphoma	Combination w/ R ²	Follicular lymphoma – 2 nd -line+ (vs R ² alone)	Phase 1b/3 confirmatory trial					
	Combination w/ R-CHOP	Follicular lymphoma – front-line 						
	Combination w/ R-CHOP	DLBCL – front-line 						
Molecularly Defined Solid Tumors	Combination w/ doxorubicin	Epithelioid sarcoma – front-line (vs doxorubicin alone)	Phase 1b/3 confirmatory trial					
	Combination w/ ASIs	Castration-resistant prostate cancer – (vs ASIs alone)	Phase 1b/2 trial					
	Monotherapy	Pediatrics with INI1-negative tumors						
PRMT INHIBITORS								
PRMT 5 Inhibitor (GSK3326595)^b		Solid tumors and blood cancers 						
PRMT 1 Inhibitor (GSK3368715)^b		Solid tumors and diffuse large B-cell lymphoma 						
OTHER TARGETS								
1 undisclosed target with Boehringer Ingelheim^c								

FOOTNOTES:

- The TAZVERIK® ES & FL indications were approved under accelerated approval. See full U.S. prescribing information at www.TAZVERIK.com
- GlaxoSmithKline holds global development and commercialization rights
- Boehringer Ingelheim and Epizyme will jointly research and develop a helicase program and share U.S. commercialization; BI holds ex-US commercialization rights

GENERAL NOTES:

Eisai holds rights to tazemetostat in Japan.
 R² = Revlimid® (lenalidomide, Celgene) + a rituximab product; ASIs = androgen signaling inhibitors